Abstract: The present invention provides a method for screening for a food ingredient or a food composition that reduces a cancer risk and inhibits cancer development. A substance that reduces a cancer risk is screened by administering a candidate substance and analyzing alteration in gut microbiota or a metabolite produced by an intestinal bacterium. Also, candidate substances are screened by adding each candidate substance to a bacterial culture system and analyzing its effect on a bacterium involved in cancer development.

Abstract: [Problem to be Solved] An object of the present invention is to provide a novel peptide that has the high ability to bind to EpCAM, which can be easily prepared by a chemical synthesis method or a genetic engineering method. [Solution] The present inventors have improved a method for screening a phage library and thereby successfully screened for a peptide that has the higher ability to bind to EpCAM compared with publicly known peptides. The present inventors have also used an already disclosed peptide having the ability to bind to EpCAM as a lead compound to prepare diverse populations of derivatives thereof, from among which a peptide strongly binding to EpCAM has been selected. The obtained peptides exhibit at least 10 times higher ability to bind to EpCAM compared with publicly known peptides and as such, are effective for the detection or diagnosis of cancer cells.

Abstract: An information processing unit includes: a diagnostic image input section that inputs the diagnostic image; an operation information obtaining section that obtains display operation history information representing an operation history of a user who controls displaying of the diagnostic image; a query image generation section that extracts a predetermined region of the input diagnostic image to generate a query image; a diagnosed image obtaining section that supplies the generated query image and the display operation history information to a diagnosed image search unit and obtains the diagnosed image obtained as a search result by the diagnosed image search unit; and a display control section that displays the diagnostic image and the obtained diagnosed image for comparison.

Abstract: The present invention provides a method capable of detecting a cancer and/or a carcinogenic risk, and a reagent for the detection thereof. The present invention also provides a method for screening for a pharmaceutical drug for reducing a carcinogenic risk and a pharmaceutical composition. Since cancer development closely correlates with alteration in gut microbiota, cancer development and/or a risk of cancer development are detected by detecting alteration in gut microbiota and a secondary bile acid produced by an intestinal bacterium. The present invention further provides a method for screening for a pharmaceutical drug with a gut microbiota as an index, and a pharmaceutical composition.

Abstract: Clothing uses a knitted fabric made from a composite thread of elastic fibers and synthetic fibers, wherein the elongation rates in the longitudinal and lateral directions as measured in accordance with the grab method of JIS-L-1096 are 160% or more and less than 250%, and the weight per unit area is 90 g/m2 or more and less than 160 g/m2. The clothing is suitable for use by patients having skin inflammations, has a comfortable texture using a knitted fabric that is light and has a high elongation rate, and does not allow seepage of medicaments or infusions.

Abstract: The present invention provides a small compound targeting at TACC3. The present invention further provides a drug, particularly, an anticancer agent, comprising the small compound targeting at TACC3. A compound represented by the general formula (I) or a pharmaceutically acceptable salt, solvate, or ester derivative thereof binds to TACC3 and inhibits cell growth. Thus, these compounds can be used as drugs, particularly, anticancer agents.

Abstract: A polynucleotide, which is a novel causative gene for cancer, is elucidated, and, based on this finding, provided are a method for detecting the polynucleotide, or a polypeptide encoded by the polynucleotide; a kit and a primer set for the detection; a method for screening an inhibitor of the polypeptide; and a pharmaceutical composition for treating a cancer containing the inhibitor. In the detection method of the present invention, an FGFR3 fusion protein, or a fusion gene encoding the fusion protein, or a TACC3 fusion protein, or a fusion gene encoding the fusion protein, is detected in a sample derived from female genitalia obtained from a subject.

Abstract: Disclosed is a recombinant plasmid having a gene which encompasses at least the entire coding region of human fibroblast interferon messenger RNA and a method for preparing such plasmid.

Abstract: A novel vaccine that can induce sufficiently high cell-mediated immunity is disclosed. The vaccine of the present invention contains, as an effective component, a polypeptide comprising a tandem repeat structure in which an MHC class I epitope region derived from an antigen protein and a spacer sequence are linked to each other alternately and repeatedly at least three times, or a recombinant vector which comprises a polynucleotide encoding said polypeptide and is capable of expressing said polypeptide in vivo. The spacer sequence is, for example, a sequence generated as an amino acid sequence inevitably encoded by a single base sequence which is designed such that the MHC class I epitope region derived from the antigen protein, an MHC class II epitope region derived from the antigen protein, and at least one higher-order-structure-stabilizing region are encoded by different reading frames in said single base sequence.

Abstract: An information processing unit includes: a diagnostic image input section that inputs the diagnostic image; an operation information obtaining section that obtains display operation history information representing an operation history of a user who controls displaying of the diagnostic image; a query image generation section that extracts a predetermined region of the input diagnostic image to generate a query image; a diagnosed image obtaining section that supplies the generated query image and the display operation history information to a diagnosed image search unit and obtains the diagnosed image obtained as a search result by the diagnosed image search unit; and a display control section that displays the diagnostic image and the obtained diagnosed image for comparison.

Abstract: Method for properly identifying and determining a target nucleic acid when the target nucleic acid is cleaved. The method includes a step of bringing a hybridization solution into contact with a target nucleic acid, wherein the hybridization solution contains a probe set that is composed of at least two labelled probes respectively labelled with different identifying factors and may hybridize with almost the full length of the sequence for the target nucleic acid. The method further includes a step of causing the identifying factors to develop the functions thereof to produce signals.

Abstract: Disclosed herein is an information processing apparatus including: a lesion progress rate recognition section configured to perform prescribed image recognition processing on a plurality of entered medical images, thereby recognizing the lesion progress rate that represents the rate of progress of the disease-induced change in living body; and a presentation control section configured to cause a presentation section to present the medical images according to the lesion progress rate which has been recognized by the lesion progress rate recognition section.

Abstract: Polynucleotides which are novel causative genes for cancer are elucidated, and a detection method of the polynucleotides or polypeptides encoded by the polynucleotides, and a kit and a primer set for detection are provided, based on the knowledge gained by the elucidation. In the detection method, a fusion gene comprising part of an SDC4, CD74, EZR, SLC34A2, LRIG3, or TPM3 gene and part of a ROS1 gene, or a fusion protein encoded by the fusion gene is detected. The primer set or the detection kit comprises a sense primer designed based on a portion encoding SDC4, CD74, EZR, SLC34A2, LRIG3, or TPM3 and an antisense primer designed based on a portion encoding ROS1.

Abstract: There is provided an image processing device including a movement section which scrolls a medical image on a screen, and a display control section which, in a case where the medical image is scrolled on the screen, controls a display section to display the medical image in a manner that an observation reference position of a diagnosis region of the medical image passes through a display reference position of a display region of the screen.

Abstract: It is intended to provide a stable metallic nanostructure that causes no aggregation when surface-modified with biomolecule-reactive functional molecules. 30 to 90% of the surface of a metallic nanostructure is covered with at least one or more types of colloid-stabilizing functional molecules. The remaining portions on the surface of the metallic nanostructure are further covered with one or more types of biologically functional molecules.

Abstract: The present invention provides a monoclonal antibody or a functional fragment thereof, capable of recognizing Aggrus epitope that includes an amino-acid sequence represented by a sequence ID 1, 3, or 4, and the monoclonal antibody or the functional fragment thereof produced from a hybridoma with accession number of FERM BP-11446, FERM BP-11447, FERM BP-11448 or FERM BP-11449. The present invention provides the hybridoma, and further an Aggrus-CLEC-2 binding inhibitor and a pharmaceutical composition for inhibition of platelet aggregation, prevention of cancer metastasis, or treatment of tumor or cancer, including the monoclonal antibody or the functional fragment thereof.

Abstract: A microscope system includes a pigment amount calculating unit, a cell component identification processing unit, a target molecule expression portion extraction unit, a cell variant setting unit, a cell variant classification determining unit, and a display image generating unit. The pigment amount calculating unit calculates a pigment amount of a molecule target pigment for each pixel of a VS image. The cell component identification processing unit identifies a cell component based on the pigment amount. The target molecule expression portion extraction unit extracts expression portions of target molecules in the area of the cell component. The cell variant setting unit sets a cell variant including a combination of presence/absence of expressions of target molecules. The cell variant classification determining unit classifies a cell area in the VS image into a cell variant based on the combination of the expression portions of the target molecules included in the cell area.

Abstract: The present invention provides a monoclonal antibody or a functional fragment thereof, capable of recognizing Aggrus epitope comprising an amino-acid sequence represented by a sequence ID 1, 3, or 4, and the monoclonal antibody or the functional fragment thereof produced from a hybridoma with deposit ID of FERM BP-11446, FERM BP-11447, FERM BP-11448 or FERM BP-11449. The present invention provides the hybridoma, and further an Aggrus-CLEC-2 binding inhibitor and a pharmaceutical composition for inhibition of platelet aggregation, prevention of cancer metastasis, or treatment of tumor or cancer, comprising the monoclonal antibody or the functional fragment thereof.

Abstract: There is provided an image processing apparatus that analyzes a pathology image obtained by imaging an analysis object including a setting device for calculating an amount of a luminance difference characteristic as an amount of characteristic of each pixel of a pathology image, and for setting a cellular tissue region in the pathology image, based on the amount of the luminance difference characteristic, using a cellular tissue detector that has studied in advance. The cellular tissue detector may have studied in advance by statistical learning that uses an image corresponding to a cellular tissue.

Abstract: Polynucleotides which are novel causative genes for cancer are elucidated, and a detection method of the polynucleotides or polypeptides encoded by the polynucleotides, and a kit and a primer set for detection are provided, based on the knowledge gained by the elucidation. In the detection method, a fusion gene comprising part of an SDC4, CD74, EZR, SLC34A2, LRIG3, or TPM3 gene and part of a ROS1 gene, or a fusion protein encoded by the fusion gene is detected. The primer set or the detection kit comprises a sense primer designed based on a portion encoding SDC4, CD74, EZR, SLC34A2, LRIG3, or TPM3 and an antisense primer designed based on a portion encoding ROS1.